Efficiency and Safety of High-frequency Radio Wave Electrotherapy With a Radio Frequency of 448 kHz in the Treatment of Patients With Organic Erectile Dysfunction.
Efficiency and Safety of High-frequency Radio Wave Electrotherapy With a Radio Frequency of 448 kHz in the Treatment of Patients With Organic Erectile Dysfunction.
Efficiency and safety of high-frequency radio wave electrotherapy with a radio frequency of
 448 kHz in the treatment of patients with organic erectile dysfunction. Sham comparator,
 parallel study including both the main and control group to demonstrate the efficiency of the
 device to treat erectile dysfunction.
The objectives of this study are:

 -  To evaluate the effectiveness of the course treatment with the apparatus for continuous
 capacitive resistive monopolar electrotherapy with a radio frequency of 448 kHz in
 patients with organic erectile dysfunction.

 -  Assess the safety and tolerability of continuous capacitive resistive monopolar
 electrotherapy with a radio frequency of 448 kHz in patients with organic erectile
 dysfunction.

 -  To evaluate the duration of the effect of continuous capacitive resistive monopolar
 electrotherapy with a radio frequency of 448 kHz.
Inclusion Criteria:

 1. Patients aged 18 to 79 years;

 2. The diagnosis is confirmed by assessing the functional criteria of arterial factors of
 panel hemodynamics (dopplerography);

 3. The diagnosis is confirmed by the assessment of the IIEF-5 questionnaire

 4. Patients with organic erectile dysfunction lasting at least 6 months.

 5. Patients with IIEF from 6 to 22 points.

 6. Patients with a permanent sexual partner for more than 3 months;

 7. Sexually Active Patients.

 Non-inclusion criteria:

 1. The use of other treatments for erectile dysfunction

 2. Age under 18 and over 79 years old;

 3. Anatomical deformation of the penis (angulation, cavernous fibrosis or Peyronie's
 disease);

 4. The presence of diseases predisposing to the development of priapism (sickle cell
 anemia, multiple myeloma, leukemia, thrombocytopenia);

 5. Running coagulation disorders;

 6. The presence of tumors in the area of electrotherapy;

 7. The presence of aneurysms in the propagation of radio frequency waves;

 8. Angina pectoris;

 9. Myocardial infarction, stroke, life-threatening arrhythmias;

 10. Thrombosis, thromboembolic disease;

 11. Arterial hypertension (blood pressure ≥ 170/90 mm Hg) or hypotension (blood pressure ≤
 90/50 mm Hg.);

 12. The patient has a mental illness that does not allow an assessment of the
 effectiveness of therapy; history of alcoholism and drug addiction;

 14. Active tuberculosis, chronic somatic diseases in the acute stage; 15. Condition after
 coronary artery bypass grafting (CABG); 16. Patient's involvement in another clinical trial
 in the last 3 months;

 Exclusion Criteria:

 1. Serious unwanted phenomenons associated with exposure to the apparatus.

 2. Incorrect inclusion in the study.

 3. A marked deterioration in the patient's condition due to an increase in the severity
 of the disease or the attachment of another disease.

 4. The patient's appearance of non-inclusion criteria during the study.

 5. Serious deviation from the protocol.

 6. The desire of the patient or his legal representative.